留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

白细胞介素-6靶向治疗前时代的中国Castleman病诊疗现状

张路 李剑

张路, 李剑. 白细胞介素-6靶向治疗前时代的中国Castleman病诊疗现状[J]. 协和医学杂志, 2023, 14(5): 911-914. doi: 10.12290/xhyxzz.2023-0227
引用本文: 张路, 李剑. 白细胞介素-6靶向治疗前时代的中国Castleman病诊疗现状[J]. 协和医学杂志, 2023, 14(5): 911-914. doi: 10.12290/xhyxzz.2023-0227
ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. doi: 10.12290/xhyxzz.2023-0227
Citation: ZHANG Lu, LI Jian. Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy[J]. Medical Journal of Peking Union Medical College Hospital, 2023, 14(5): 911-914. doi: 10.12290/xhyxzz.2023-0227

白细胞介素-6靶向治疗前时代的中国Castleman病诊疗现状

doi: 10.12290/xhyxzz.2023-0227
基金项目: 

中央高水平医院临床科研专项 2022-PUMCH-A-021

北京市科技计划课题 Z211100002921016

北京市东城区优秀人才培养经费 2022-dchrcpyzz-69

详细信息
    通讯作者:

    李剑, E-mail: lijian@pumch.cn

  • 中图分类号: R552;R825.5;R730.51

Castleman Disease in China: State-of-the-art Technology Before the Era of IL-6 Targeted Therapy

Funds: 

National High Level Hospital Clinical Research Funding 2022-PUMCH-A-021

Beijing Municipal Commission of Sciences and Technology Z211100002921016

Dongcheng District Outstanding Talent Nurturing Program 2022-dchrcpyzz-69

More Information
  • 摘要: Castleman病是纳入我国《第一批罕见病目录》的罕见血液系统疾病,该病临床异质性强,分为多种亚型。其中,特发性多中心型Castleman病(idiopathic multicentric Castleman disease,iMCD)病情重、预后差,是临床医师面临的重大挑战。白细胞介素(interleukin,IL)-6靶向药物(如司妥昔单抗)是国内外多个指南、共识推荐治疗iMCD的首选药物,2022年7月司妥昔单抗在国内上市,标志着我国针对iMCD的IL-6靶向治疗时代的开启。IL-6靶间治疗已在国内陆续展开,本文阐述过去20年间(IL-6靶向治疗前时代)中国Castleman病的诊疗现状,以及国内研究者在该领域取得的研究成果。
    作者贡献:张路负责文献复习和论文初稿撰写;李剑负责论文审阅及修改。
    利益冲突:所有作者均声明不存在利益冲突
  • 图  1  依托中国Castleman病协作组的国内多中心回顾性研究纳入的CD患者临床分型

    CD:Castleman病;UCD:单中心型Castleman病;MCD:多中心型Castleman病;HHV-8:人类疱疹病毒-8;aMCD:无症状性MCD;iMCD:特发性多中心型Castleman病;iMCD-TAFRD: iMCD-TAFRD综合征;iMCD-NOS:iMCD-非特指型;IPL:特发性浆细胞性淋巴结病

  • [1] Castleman B, Iverson L, Menendez VP. Localized mediastinal lymphnode hyperplasia resembling thymoma[J]. Cancer, 1956, 9: 822-830. doi:  10.1002/1097-0142(195607/08)9:4<822::AID-CNCR2820090430>3.0.CO;2-4
    [2] Zhang L, Dong YJ, Peng HL, et al. A national, multicenter, retrospective study of Castleman disease in China implementing CDCN criteria[J]. Lancet Reg Health West Pac, 2023, 34: 100720. doi:  10.1016/j.lanwpc.2023.100720
    [3] van Rhee F, Voorhees P, Dispenzieri A, et al. International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease[J]. Blood, 2018, 132: 2115-2124.
    [4] Fajgenbaum DC, Uldrick TS, Bagg A, et al. International, evidence-based consensus diagnostic criteria for HHV-8-negative/idiopathic multicentric Castleman disease[J]. Blood, 2017, 129: 1646-1657. doi:  10.1182/blood-2016-10-746933
    [5] 中华医学会血液学分会淋巴细胞疾病学组, 中国抗癌协会血液肿瘤专业委员会, 中国Castleman病协作组. 中国Castleman病诊断与治疗专家共识(2021年版)[J]. 中华血液学杂志, 2021, 42: 529-534. https://www.cnki.com.cn/Article/CJFDTOTAL-ZWWK202107001.htm
    [6] Zhang MY, Jia MN, Chen J, et al. UCD with MCD-like inflammatory state: surgical excision is highly effective[J]. Blood Adv, 2021, 5: 122-128. doi:  10.1182/bloodadvances.2020003607
    [7] Dong Y, Zhang L, Nong L, et al. Effectiveness of rituximab-containing treatment regimens in idiopathic multicentric Castleman disease[J]. Ann Hematol, 2018, 97: 1641-1647. doi:  10.1007/s00277-018-3347-0
    [8] Zhang L, Zhao AL, Duan MH, et al. Phase 2 study using oral thalidomide-cyclophosphamide-prednisone for idiopathic multicentric Castleman disease[J]. Blood, 2019, 133: 1720-1728. doi:  10.1182/blood-2018-11-884577
    [9] Li Z, Lan X, Li C, et al. Recurrent PDGFRB mutations in unicentric Castleman disease[J]. Leukemia, 2019, 33: 1035-1038. doi:  10.1038/s41375-018-0323-6
    [10] Yu L, Shi M, Cai Q, et al. A Novel Predictive Model for Idiopathic Multicentric Castleman Disease: The International Castleman Disease Consortium Study[J]. Oncologist, 2020, 25: 963-973. doi:  10.1634/theoncologist.2019-0986
    [11] Zhou J, Zhang L, Liu X, et al. Evolution of Pulmonary Involvement in Idiopathic Multicentric Castleman Disease-Not Otherwise Specified: From Nodules to Cysts or Consolidation[J]. Chest, 2023. doi:  10.1016/j.chest.2023.03.022.
    [12] Zhao H, Zhang M, Shen K, et al. A phase 2 prospective study of bortezomib, cyclophosphamide, and dexamethasone in newly-diagnosed iMCD patients[J]. Blood, 2023, 141: 2654-2657.
    [13] Zhong NN, Liu B, Bu LL. Exploring Castleman disease in China: pre-IL-6 treatment era and advancements in knowledge[J]. Lancet Reg Health West Pac, 2023, 34: 100747. doi:  10.1016/j.lanwpc.2023.100747
  • 加载中
图(1)
计量
  • 文章访问数:  216
  • HTML全文浏览量:  61
  • PDF下载量:  69
  • 被引次数: 0
出版历程
  • 收稿日期:  2023-05-08
  • 录用日期:  2023-06-26
  • 网络出版日期:  2023-07-13
  • 刊出日期:  2023-09-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!